Top San Francisco Bay Area, CA Pharmaceutical Companies (54)
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. We are powered by technology. Our Global Research Technologies, Medical Devices as a software, and Data Science teams are on the cutting edge of developing and supporting our life-saving medications.
Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely and accurate patient dosing. Endpoint is headquartered in Raleigh-Durham, North Carolina with offices across the United States, Europe, and Asia.
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is to help Americans find convenient and affordable healthcare. We offer solutions for consumers, employers, health plans, and anyone else who shares our desire to provide affordable prescriptions to all Americans. We’re committed to growing and empowering a more inclusive community within our company and industry. That’s why we hire and cultivate diverse teams of the best and brightest from all backgrounds, experiences, and perspectives. We believe that true innovation happens when everyone has a seat at the table and the tools, resources, and opportunities to excel. Come join and help us create the future of healthcare.
We use data to understand what specialty drugs do at the individual, not population level. Our specialty drug management product, VIVIO Precision Care™ fixes big unsolved healthcare problems: expensive drug therapies that don’t work; lack of real-world effectiveness; doctors prescribing based on opinion and experience instead of data; the arbitrary line between pharmacy drug and medical benefit; and, egregious supply chain waste. We replace the current pharma-centric therapeutic model with our data-centric one and drive better patient outcomes without overpaying. Employees and physicians have access to the right drugs based on individual data rather than self-serving policies. Typically, we save large and mid-sized self-insured employers 25-35% of their current spend.
Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. Our Founders and members of the Board are a group of esteemed, world-class scientists from the University of California, San Francisco: Nevan Krogan, Kevan Shokat, Sourav Bandyopadhyay, Natalia Jura, as well as renowned biotech executives George Scangos and Norbert Bischofberger. These leaders bring with them a strong track record of amazing discoveries and scientific breakthroughs, leading to very successful companies and many FDA approved drugs.
Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Berkeley, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more about our mission to decode the language of life with AI, visit profluent.bio
At Enable Medicine, we index biological data into highly detailed maps of human disease. This atlas is utilized to guide novel drug target discovery, identify biomarkers of therapeutic response, and develop optimal treatment strategies. Our lab in Menlo Park, California, generates high-parameter biological datasets, and our cloud-based operating system allows researchers to organize, process, query, and analyze this data at scale. Taken together, our platform unlocks the ability to search biology, where complex questions about human disease can be asked and answered for the first time. We build and provide these capabilities to our network of leading academic institutions and pharmaceutical companies around the world. Our collaborative research spans numerous indications, with a core focus on unmet needs in oncology and autoimmune diseases. We advance science by accelerating data generation, methods development, research insights, and high-impact publications. Our interdisciplinary team of scientists, engineers, researchers, and investors focuses on decoding biological systems to make drug discovery, development, and patient care more deterministic. Come join us on our mission to decipher biology and meaningfully improve the way patients are treated.
WithMe Health is an innovative pharmacy benefits company that works directly with employers and health benefit vendors to provide you and your family with easy to understand pharmacy benefits. WithMe provides personalized medication guidance, with hands-on support from Medication Guides (expert pharmacists and pharmacy technicians) as well as an easy-to-use mobile app to help you manage your medications and see ways to save money. Our mission is to create a significantly better medication experience for all our members, putting their health and needs first as they navigate the complexity of medications by offering our clinical expertise to them and their trusted providers to save them money and to improve their health. We’re unsatisfied with the status quo in pharmacy benefits management and medication guidance. We know that we can provide an easier and more personalized, cost-effective, and equitable experience for members, while helping our clients--those who provide pharmacy benefits--make a more impactful investment in their members’ health. To date, we’ve raised over $40 million from Oak HC/FT, OMERS Ventures, and other leading healthcare VCs and strategic partners to take on the $450+ billion PBM industry.
Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.
Zogenix engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with mast-cell mediated inflammatory diseases. By inhibiting KIT, we believe we can provide broad symptomatic relief to patients with a range of disorders, including chronic spontaneous urticaria and severe asthma
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities
Invitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://eikontx.com/team#positions
SHYFT Analytics is an industry leader in cloud data management and mobile analytics for the global life sciences industry. SHYFT is used by pharmaceutical, biotech, medical device and other healthcare leaders from around the globe and across thousands of users. With over 10 years innovating in life sciences, SHYFT’s industry cloud platform is leading the transformation in healthcare and helping our customers succeed. Designed for healthcare, the SHYFT Platform is the fastest way to transform clinical and commercial data into novel insights and achieve significant scale and agility. The platform features product analytic solutions for Specialty, Launch, Real World Evidence, Market Access, Rare Disease and Sales. Learn more at www.ShyftAnalytics.com.
A start-up developing novel ophthalmic therapeutics to treat major unmet needs for patients.
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders. The more innovative solutions developed, the more lives BioMarin can impact. Recruitment Fraud Alert Notice Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent BioMarin in recruitment activities. We have an established recruitment process which is required for all posted positions by BioMarin prior to issuing an offer of employment. This BioMarin process requires formal interviews conducted live with personnel representing BioMarin and never requires payments or fees from job applicants. BioMarin does not conduct interviews via texting tools such as RingCentral. In the event you receive a suspicious email message about recruiting on behalf of BioMarin, unless it’s from a BioMarin authorized recruiting partner, do not provide any personal information or pay any fees. Qualified and interested candidates should apply to current openings directly through this BioMarin website. BioMarin accepts no responsibility for any costs or charges incurred as a result of fraudulent activity. If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the FBI via www.ic3.gov. We would also suggest you notify your local police department and monitor your credit. We appreciate your interest in BioMarin & encourage you to visit http://careers.biomarin.com/career-areas to review job opportunities.
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.
Pliant Therapeutics is a late-stage clinical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates aimed at halting or even reversing fibrotic diseases and address the unmet needs of many patients. Pliant’s co-founders include world-renowned researchers from the University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
Work Your Passion. Live Your Purpose.
Industry
Work Your Passion. Live Your Purpose.
